Article(id=1330225086377866058, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225010435796998, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.02.018, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1624464000000, receivedDateStr=2021-06-24, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795079974979, onlineDateStr=2026-11-19, pubDate=1644422400000, pubDateStr=2022-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795079974979, onlineIssueDateStr=2026-11-19, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795079974979, creator=13701087609, updateTime=1795079974979, updator=13701087609, issue=Issue{id=1330225010435796998, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='2', pageStart='109', pageEnd='209', issueExtLink='null', onlineDate='null', pubDate='1644422400000', pubDateStr='2022-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795079956873, creator='13701087609', updateTime=1795084674007, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330244795886318219, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225010435796998, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330244795886318220, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1330225010435796998, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=205, endPage=209, ext={EN=ArticleExt(id=1330225086574998347, articleId=1330225086377866058, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Neuromuscular adverse events associated with programmed cell death-1 inhibitors, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

As an important immune checkpoint inhibitor, programmed cell death-1 (PD-1) is preferentially expressed in B cells, T cells and natural killer cell. PD-1 has two ligands: programmed death-ligand (PD-1)1 and PD-L2. PD-1 can prevent T cell over activation and down-regulate immune response, and plays an important role in reducing autoimmune response and promoting self tolerance. PD-1 signaling is used by tumors to escape immune killing. In recent years, a variety of PD-1 signaling inhibitors have been approved by FDA to induce anti-tumor immune response, which have achieved certain clinical efficacy, but many adverse drug reactions also occur in the treatment process. In this article, we reviewed the neuromuscular complications of PD-1 inhibitors in neurology in order to provide reference for standardized application of PD-1 inhibitors.

, authors=Liuqing WANG1, 2, Yongwei WANG1, Rongzhen XU3, *, authorsList=Liuqing WANG, Yongwei WANG, Rongzhen XU, authorCompany=null, correspAuthors=Rongzhen XU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1330225086776324940, articleId=1330225086377866058, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=程序性细胞死亡蛋白-1抑制剂的神经肌肉不良反应, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

程序性细胞死亡蛋白-1(programmed cell death-1,PD-1)可优先在机体B细胞、T细胞和自然杀伤细胞中表达,是一种重要的免疫检查点抑制剂。PD-1有两个配体,即程序性死亡配体(programmed death-ligand,PD-L)1和PD-L2。PD-1可防止T细胞过度活化和下调免疫应答,在降低自身免疫反应和促进自身耐受中发挥重要作用。PD-1信号被肿瘤用于逃避免疫杀死,近年来FDA批准多种PD-1抑制剂被用于诱导抗肿瘤免疫应答并取得一定临床疗效,但在治疗过程中也发生很多药物不良反应。该文对PD-1抑制剂在神经科应用过程中产生的神经肌肉并发症等进行综述,以期为PD-1抑制剂规范应用提供参考。

, authors=王柳清1, 2, 王永伟1, 徐蓉贞3, *, authorsList=王柳清, 王永伟, 徐蓉贞, authorCompany=null, correspAuthors=徐蓉贞, authorNote=

王柳清,博士,主治医师,研究方向:脑血管疾病、神经免疫性疾病及神经电生理等。

, correspAuthorsNote=
徐蓉贞,副主任医师,研究方向:卒中后神经功能康复、神经免疫性疾病诊疗及功能康复等。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=H1IRZuQPqh6VfccA3Q6gZw==, magXml=yElNPIsLtYKMAmHrtsvAPA==, pdfUrl=null, pdf=0RDDwMGibfXtXqE1yqThyg==, pdfFileSize=1753230, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=r6GZMyc3AH2/FLS8UDRy6g==, mapNumber=null, fund=null)}, authors=[Author(id=1330225088806368087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225088907031386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225088806368087, language=EN, stringName=Liuqing WANG, firstName=Liuqing, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China
2.Department of Neurology, The First Affiliated Hospital of Soochow, Suzhou 215006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225088990917467, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225088806368087, language=CN, stringName=王柳清, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.南京市高淳人民医院神经内科,江苏 南京 211300
2.苏州市附属第一医院神经内科,江苏 苏州 215006, bio={"content":"

王柳清,博士,主治医师,研究方向:脑血管疾病、神经免疫性疾病及神经电生理等。

"}, bioImg=null, bioContent=

王柳清,博士,主治医师,研究方向:脑血管疾病、神经免疫性疾病及神经电生理等。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225086986040141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=1., ext=[AuthorCompanyExt(id=1330225086994428750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225087007011663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.南京市高淳人民医院神经内科,江苏 南京 211300)]), AuthorCompany(id=1330225088626013008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=2., ext=[AuthorCompanyExt(id=1330225088634401617, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088626013008, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Neurology, The First Affiliated Hospital of Soochow, Suzhou 215006, Jiangsu Province, China), AuthorCompanyExt(id=1330225088642790226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088626013008, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.苏州市附属第一医院神经内科,江苏 苏州 215006)])]), Author(id=1330225089053832029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225089129329503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089053832029, language=EN, stringName=Yongwei WANG, firstName=Yongwei, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225089188049760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089053832029, language=CN, stringName=王永伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.南京市高淳人民医院神经内科,江苏 南京 211300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225086986040141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=1., ext=[AuthorCompanyExt(id=1330225086994428750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225087007011663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.南京市高淳人民医院神经内科,江苏 南京 211300)])]), Author(id=1330225089246770018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225089322267492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089246770018, language=EN, stringName=Rongzhen XU, firstName=Rongzhen, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.Department of Rehabilitation, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225089385182053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089246770018, language=CN, stringName=徐蓉贞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.南京市高淳人民医院康复科,江苏 南京 211300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225088718287699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=3., ext=[AuthorCompanyExt(id=1330225088730870612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088718287699, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Rehabilitation, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225088735064917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088718287699, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.南京市高淳人民医院康复科,江苏 南京 211300)])])], keywords=[Keyword(id=1330225089511011174, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=EN, orderNo=1, keyword=programmed cell death protein-1), Keyword(id=1330225089578120039, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=EN, orderNo=2, keyword=programmed cell death-1 inhibitor), Keyword(id=1330225089649423210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=EN, orderNo=3, keyword=tumor), Keyword(id=1330225089724920683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=EN, orderNo=4, keyword=immune response), Keyword(id=1330225089783640940, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=EN, orderNo=5, keyword=neuvo muscular), Keyword(id=1330225089842361197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=EN, orderNo=6, keyword=adverse reactions), Keyword(id=1330225089905275758, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=CN, orderNo=1, keyword=程序性细胞死亡蛋白-1), Keyword(id=1330225090001744751, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=CN, orderNo=2, keyword=程序性细胞死亡蛋白-1抑制剂), Keyword(id=1330225090064659312, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=CN, orderNo=3, keyword=免疫应答), Keyword(id=1330225090144351089, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=CN, orderNo=4, keyword=神经肌肉), Keyword(id=1330225090198877042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, language=CN, orderNo=5, keyword=不良反应)], refs=[Reference(id=1330225090379232116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242., articleTitle=null, refAbstract=null), Reference(id=1330225090450535285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Vinay DS, Kwon BS. Harnessing immune checkpoints for cancer therapy[J]. Immunotherapy, 2018, 10(14): 1265-1284., articleTitle=null, refAbstract=null), Reference(id=1330225090534421366, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Shi T, Ma Y, Yu L, et al. Cancer immunotherapy: a focus on the regulation of immune checkpoints[J]. Int J Mol Sci, 2018, 19(5): 1389., articleTitle=null, refAbstract=null), Reference(id=1330225090601530231, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway[J]. Nat Rev Immunol, 2018, 18(3): 153-167., articleTitle=null, refAbstract=null), Reference(id=1330225090668639096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Savelyeva N, Allen A, Chotprakaikiat W, et al. Linked CD4 T cell help: broadening immune attack against cancer by vaccination[J]. Curr Top Microbiol Immunol, 2017, 405: 123-143., articleTitle=null, refAbstract=null), Reference(id=1330225090731553657, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Lu G, Qiu Y, Su X. Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer[J]. Eur J Pharm Sci, 2021, 157: 105606., articleTitle=null, refAbstract=null), Reference(id=1330225090798662522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Du W, Chen C, Sun P, et al. Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy[J]. Nanoscale, 2020, 12(5): 3317-3329., articleTitle=null, refAbstract=null), Reference(id=1330225090865771387, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1): 8., articleTitle=null, refAbstract=null), Reference(id=1330225090945463164, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade[J]. J Neuroophthalmol, 2021, 41(4): 519-530., articleTitle=null, refAbstract=null), Reference(id=1330225091020960637, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors[J]. Curr Neurol Neurosci Rep, 2018, 18(10): 63., articleTitle=null, refAbstract=null), Reference(id=1330225091130012542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan[J]. Neurology, 2017, 89(11): 1127-1134., articleTitle=null, refAbstract=null), Reference(id=1330225091201315711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies[J]. J Immunother, 2018, 41(4): 208-211., articleTitle=null, refAbstract=null), Reference(id=1330225091264230272, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors[J]. Eur J Cancer, 2017, 82: 128-136., articleTitle=null, refAbstract=null), Reference(id=1330225091331339137, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolumab treatment[J]. Muscle Nerve, 2016, 54(3): 507-509., articleTitle=null, refAbstract=null), Reference(id=1330225091394253698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Gonzalez NL, Puwanant A, Lu A, et al. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review[J]. Neuromuscul Disord, 2017, 27(3): 266-268., articleTitle=null, refAbstract=null), Reference(id=1330225091469751171, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Behling J, Kaes J, Munzel T, et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma[J]. Melanoma Res, 2017, 27(2): 155-158., articleTitle=null, refAbstract=null), Reference(id=1330225091532665732, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Milone M. Diagnosis and management of immune-mediated myopathies[J]. Mayo Clin Proc, 2017, 92(5): 826-837., articleTitle=null, refAbstract=null), Reference(id=1330225093130695557, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Diamantopoulos PT, Tsatsou K, Benopoulou O, et al. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment[J]. J Immunother, 2017, 40(6): 221-223., articleTitle=null, refAbstract=null), Reference(id=1330225093193610118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Tan RYC, Toh CK, Takano A. Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis[J]. J Thorac Oncol, 2017, 12(7): e90-e91., articleTitle=null, refAbstract=null), Reference(id=1330225093248136071, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933., articleTitle=null, refAbstract=null), Reference(id=1330225093311050632, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Vallet H, Gaillet A, Weiss N, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma[J]. Ann Oncol, 2016, 27(7): 1352-1353., articleTitle=null, refAbstract=null), Reference(id=1330225093382353801, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody[J]. J Immunother Cancer, 2016, 4: 36., articleTitle=null, refAbstract=null), Reference(id=1330225093466239882, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab[J]. Cancer Sci, 2016, 107(7): 1055-1058., articleTitle=null, refAbstract=null), Reference(id=1330225093524960139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity[J]. Nature, 2017, 545(7655): 495-499., articleTitle=null, refAbstract=null), Reference(id=1330225093579486092, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Kahler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2016, 14(7): 662-681., articleTitle=null, refAbstract=null), Reference(id=1330225093646594957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Anderson D, Beecher G, Nathoo N, et al. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors[J]. Neurooncol Pract, 2019, 6(5): 340-345., articleTitle=null, refAbstract=null), Reference(id=1330225093709509518, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors[J]. Expert Opin Drug Saf, 2020, 19(4): 479-488., articleTitle=null, refAbstract=null), Reference(id=1330225093793395599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Schneiderbauer R, Schneiderbauer M, Wick W, et al. PD-1 antibody-induced Guillain-Barré syndrome in a patient with metastatic melanoma[J]. Acta Derm Venereol, 2017, 97(3): 395-396., articleTitle=null, refAbstract=null), Reference(id=1330225093856310160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy[J]. N Engl J Med, 2016, 375(3): 296-297., articleTitle=null, refAbstract=null), Reference(id=1330225093990527889, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report[J]. Jpn J Clin Oncol, 2016, 46(9): 875-878., articleTitle=null, refAbstract=null), Reference(id=1330225094066025362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Sepulveda M, Martinez-Hernandez E, Gaba L, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma[J]. Muscle Nerve, 2017, 56(6): E162-E167., articleTitle=null, refAbstract=null)], funds=[Fund(id=1330225090291151731, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, awardId=GYK-2021-005, language=CN, fundingSource=高淳人民医院院级课题(GYK-2021-005), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1330225086986040141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=1., ext=[AuthorCompanyExt(id=1330225086994428750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225087007011663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.南京市高淳人民医院神经内科,江苏 南京 211300)]), AuthorCompany(id=1330225088626013008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=2., ext=[AuthorCompanyExt(id=1330225088634401617, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088626013008, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Neurology, The First Affiliated Hospital of Soochow, Suzhou 215006, Jiangsu Province, China), AuthorCompanyExt(id=1330225088642790226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088626013008, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.苏州市附属第一医院神经内科,江苏 苏州 215006)]), AuthorCompany(id=1330225088718287699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=3., ext=[AuthorCompanyExt(id=1330225088730870612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088718287699, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Rehabilitation, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225088735064917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088718287699, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.南京市高淳人民医院康复科,江苏 南京 211300)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.02.018, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.02.018, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.02.018, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.02.018, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1644422400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
程序性细胞死亡蛋白-1抑制剂的神经肌肉不良反应
王柳清 1, 2 , 王永伟 1 , 徐蓉贞 3, *
世界临床药物 | 综述评论 2022,43(2): 205-209
收起
收藏切换
世界临床药物 |综述评论 2022 , 43 (2) : 205 -209
程序性细胞死亡蛋白-1抑制剂的神经肌肉不良反应
全屏
[Author(id=1330225088806368087, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225088907031386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225088806368087, language=EN, stringName=Liuqing WANG, firstName=Liuqing, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China
2.Department of Neurology, The First Affiliated Hospital of Soochow, Suzhou 215006, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225088990917467, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225088806368087, language=CN, stringName=王柳清, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.南京市高淳人民医院神经内科,江苏 南京 211300
2.苏州市附属第一医院神经内科,江苏 苏州 215006, bio={"content":"

王柳清,博士,主治医师,研究方向:脑血管疾病、神经免疫性疾病及神经电生理等。

"}, bioImg=null, bioContent=

王柳清,博士,主治医师,研究方向:脑血管疾病、神经免疫性疾病及神经电生理等。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225086986040141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=1., ext=[AuthorCompanyExt(id=1330225086994428750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225087007011663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.南京市高淳人民医院神经内科,江苏 南京 211300)]), AuthorCompany(id=1330225088626013008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=2., ext=[AuthorCompanyExt(id=1330225088634401617, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088626013008, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Neurology, The First Affiliated Hospital of Soochow, Suzhou 215006, Jiangsu Province, China), AuthorCompanyExt(id=1330225088642790226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088626013008, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.苏州市附属第一医院神经内科,江苏 苏州 215006)])]), Author(id=1330225089053832029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330225089129329503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089053832029, language=EN, stringName=Yongwei WANG, firstName=Yongwei, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225089188049760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089053832029, language=CN, stringName=王永伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.南京市高淳人民医院神经内科,江苏 南京 211300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225086986040141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=1., ext=[AuthorCompanyExt(id=1330225086994428750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225087007011663, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225086986040141, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.南京市高淳人民医院神经内科,江苏 南京 211300)])]), Author(id=1330225089246770018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330225089322267492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089246770018, language=EN, stringName=Rongzhen XU, firstName=Rongzhen, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.Department of Rehabilitation, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330225089385182053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, authorId=1330225089246770018, language=CN, stringName=徐蓉贞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, *, address=3.南京市高淳人民医院康复科,江苏 南京 211300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330225088718287699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, xref=3., ext=[AuthorCompanyExt(id=1330225088730870612, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088718287699, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of Rehabilitation, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China), AuthorCompanyExt(id=1330225088735064917, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1330225086377866058, companyId=1330225088718287699, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.南京市高淳人民医院康复科,江苏 南京 211300)])])]
王柳清1, 2, 王永伟1, 徐蓉贞3, *
作者信息
  • 1.南京市高淳人民医院神经内科,江苏 南京 211300
  • 2.苏州市附属第一医院神经内科,江苏 苏州 215006
  • 3.南京市高淳人民医院康复科,江苏 南京 211300
通讯作者:
徐蓉贞,副主任医师,研究方向:卒中后神经功能康复、神经免疫性疾病诊疗及功能康复等。
作者简介:

王柳清,博士,主治医师,研究方向:脑血管疾病、神经免疫性疾病及神经电生理等。

Neuromuscular adverse events associated with programmed cell death-1 inhibitors
Liuqing WANG1, 2, Yongwei WANG1, Rongzhen XU3, *
Affiliations
  • 1.Department of Neurology, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China
  • 2.Department of Neurology, The First Affiliated Hospital of Soochow, Suzhou 215006, Jiangsu Province, China
  • 3.Department of Rehabilitation, Nanjing Gaochun People's Hospital, Nanjing 211300, Jiangsu Province, China
出版时间: 2022-02-10 doi: 10.13683/j.wph.2022.02.018
文章导航
收藏切换

程序性细胞死亡蛋白-1(programmed cell death-1,PD-1)可优先在机体B细胞、T细胞和自然杀伤细胞中表达,是一种重要的免疫检查点抑制剂。PD-1有两个配体,即程序性死亡配体(programmed death-ligand,PD-L)1和PD-L2。PD-1可防止T细胞过度活化和下调免疫应答,在降低自身免疫反应和促进自身耐受中发挥重要作用。PD-1信号被肿瘤用于逃避免疫杀死,近年来FDA批准多种PD-1抑制剂被用于诱导抗肿瘤免疫应答并取得一定临床疗效,但在治疗过程中也发生很多药物不良反应。该文对PD-1抑制剂在神经科应用过程中产生的神经肌肉并发症等进行综述,以期为PD-1抑制剂规范应用提供参考。

程序性细胞死亡蛋白-1  /  程序性细胞死亡蛋白-1抑制剂  /  免疫应答  /  神经肌肉  /  不良反应

As an important immune checkpoint inhibitor, programmed cell death-1 (PD-1) is preferentially expressed in B cells, T cells and natural killer cell. PD-1 has two ligands: programmed death-ligand (PD-1)1 and PD-L2. PD-1 can prevent T cell over activation and down-regulate immune response, and plays an important role in reducing autoimmune response and promoting self tolerance. PD-1 signaling is used by tumors to escape immune killing. In recent years, a variety of PD-1 signaling inhibitors have been approved by FDA to induce anti-tumor immune response, which have achieved certain clinical efficacy, but many adverse drug reactions also occur in the treatment process. In this article, we reviewed the neuromuscular complications of PD-1 inhibitors in neurology in order to provide reference for standardized application of PD-1 inhibitors.

programmed cell death protein-1  /  programmed cell death-1 inhibitor  /  tumor  /  immune response  /  neuvo muscular  /  adverse reactions
王柳清, 王永伟, 徐蓉贞. 程序性细胞死亡蛋白-1抑制剂的神经肌肉不良反应. 世界临床药物, 2022 , 43 (2) : 205 -209 . DOI: 10.13683/j.wph.2022.02.018
Liuqing WANG, Yongwei WANG, Rongzhen XU. Neuromuscular adverse events associated with programmed cell death-1 inhibitors[J]. World Clinical Drug, 2022 , 43 (2) : 205 -209 . DOI: 10.13683/j.wph.2022.02.018
  • 高淳人民医院院级课题(GYK-2021-005)
参考文献 引证文献
排序方式:
[1]
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242.
[2]
Vinay DS, Kwon BS. Harnessing immune checkpoints for cancer therapy[J]. Immunotherapy, 2018, 10(14): 1265-1284.
[3]
Shi T, Ma Y, Yu L, et al. Cancer immunotherapy: a focus on the regulation of immune checkpoints[J]. Int J Mol Sci, 2018, 19(5): 1389.
[4]
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway[J]. Nat Rev Immunol, 2018, 18(3): 153-167.
[5]
Savelyeva N, Allen A, Chotprakaikiat W, et al. Linked CD4 T cell help: broadening immune attack against cancer by vaccination[J]. Curr Top Microbiol Immunol, 2017, 405: 123-143.
[6]
Lu G, Qiu Y, Su X. Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer[J]. Eur J Pharm Sci, 2021, 157: 105606.
[7]
Du W, Chen C, Sun P, et al. Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy[J]. Nanoscale, 2020, 12(5): 3317-3329.
[8]
Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1): 8.
[9]
Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade[J]. J Neuroophthalmol, 2021, 41(4): 519-530.
[10]
Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors[J]. Curr Neurol Neurosci Rep, 2018, 18(10): 63.
[11]
Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan[J]. Neurology, 2017, 89(11): 1127-1134.
[12]
Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies[J]. J Immunother, 2018, 41(4): 208-211.
[13]
Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors[J]. Eur J Cancer, 2017, 82: 128-136.
[14]
Sciacca G, Nicoletti A, Rampello L, et al. Benign form of myasthenia gravis after nivolumab treatment[J]. Muscle Nerve, 2016, 54(3): 507-509.
[15]
Gonzalez NL, Puwanant A, Lu A, et al. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review[J]. Neuromuscul Disord, 2017, 27(3): 266-268.
[16]
Behling J, Kaes J, Munzel T, et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma[J]. Melanoma Res, 2017, 27(2): 155-158.
[17]
Milone M. Diagnosis and management of immune-mediated myopathies[J]. Mayo Clin Proc, 2017, 92(5): 826-837.
[18]
Diamantopoulos PT, Tsatsou K, Benopoulou O, et al. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment[J]. J Immunother, 2017, 40(6): 221-223.
[19]
Tan RYC, Toh CK, Takano A. Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis[J]. J Thorac Oncol, 2017, 12(7): e90-e91.
[20]
Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933.
[21]
Vallet H, Gaillet A, Weiss N, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma[J]. Ann Oncol, 2016, 27(7): 1352-1353.
[22]
Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody[J]. J Immunother Cancer, 2016, 4: 36.
[23]
Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab[J]. Cancer Sci, 2016, 107(7): 1055-1058.
[24]
Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity[J]. Nature, 2017, 545(7655): 495-499.
[25]
Kahler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2016, 14(7): 662-681.
[26]
Anderson D, Beecher G, Nathoo N, et al. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors[J]. Neurooncol Pract, 2019, 6(5): 340-345.
[27]
Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors[J]. Expert Opin Drug Saf, 2020, 19(4): 479-488.
[28]
Schneiderbauer R, Schneiderbauer M, Wick W, et al. PD-1 antibody-induced Guillain-Barré syndrome in a patient with metastatic melanoma[J]. Acta Derm Venereol, 2017, 97(3): 395-396.
[29]
de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy[J]. N Engl J Med, 2016, 375(3): 296-297.
[30]
Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report[J]. Jpn J Clin Oncol, 2016, 46(9): 875-878.
[31]
Sepulveda M, Martinez-Hernandez E, Gaba L, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma[J]. Muscle Nerve, 2017, 56(6): E162-E167.
2022年第43卷第2期
11
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.02.018
  • 接收时间:2021-06-24
  • 首发时间:2026-11-19
  • 出版时间:2022-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2021-06-24
基金
高淳人民医院院级课题(GYK-2021-005)
作者信息
    1.南京市高淳人民医院神经内科,江苏 南京 211300
    2.苏州市附属第一医院神经内科,江苏 苏州 215006
    3.南京市高淳人民医院康复科,江苏 南京 211300

通讯作者:

徐蓉贞,副主任医师,研究方向:卒中后神经功能康复、神经免疫性疾病诊疗及功能康复等。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.02.018
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏